

Pharmacist Protocol for Prescribing and Dispensing Naloxone HCI Outside the Licensed Pharmacy Premise

	T		
Purpose	This protocol allows Connecticut licensed pharmacists who have		
	successfully completed an approved naloxone training certification		
	course in accordance with Section 6(b) of Connecticut Public Act 15-198		
	to prescribe and dispense Naloxone HCI outside of a Connecticut		
	licensed pharmacy premise and within the confines of the State of		
	Connecticut.		
Notification	The State of Connecticut Department of Consumer Protection shall be		
	notified in writing via electronic mail, facsimile or U.S. Mail at least 30 days		
	prior to a Connecticut licensed pharmacist prescribing and dispensing		
	Naloxone HCI outside a Connecticut licensed pharmacy and within the		
	confines of the State of Connecticut. Said notification shall include, but not		
	be limited to, the location(s) at which Naloxone HCI will be prescribed and		
	dispensed, the date(s), the time(s) and the name of each pharmacist		
	prescribing and dispensing Naloxone HCI outside a Connecticut licensed		
	pharmacy and within the confines of the State of Connecticut.		
Medication		Naloxone HCI 2mg/2ml prefilled syringe with atomizer	
	Intranasal	Naloxone HCI 4mg/0.1ml nasal spray (i.e. Narcan®)	
		Naloxone HCI 0.4mg/ml autoinjector (i.e. Evzio®)	
	Intramuscular	Naloxone HCl 0.4mg/ml single dose vial with 3ml 25gx1"	
		syringe	
Inventory	Naloxone HCl ir	nventory shall be tracked and signed in and out of the	
	same licensed pharmacy premise by a Connecticut licensed pharmacist.		
Security		hall remain in the possession of a Connecticut licensed	
	pharmacist at all times and shall be stored in a container capable of being		
		lock or numbered tear-away-type inventory control tag at	
	all times when removed from the licensed pharmacy premise, except for		
	the necessary to actively dispense Naloxone HCI.		
	Naloxone HCI shall be removed from and returned to the same		
		acy premise in a timely manner on the same day.	
Storage		hall be stored in accordance with manufacturer guidelines	
J		onment that protects from extreme temperature changes and	
	bright light.	and the second of the second o	
Integrity		tock shall be inspected prior to dispensing outside the	
		acy premise and upon return to the licensed pharmacy	
	•	ure stock has not been adulterated during transport and	
	storage.	and the second s	
Labeling	Each intranasal	and intramuscular Naloxone HCl dispensed shall be labeled	
		with all applicable federal and state laws.	
		11	

450 Columbus Boulevard, Suite 901, Hartford, Connecticut 06103 Phone: (860) 713-6065 Fax: (860) 713-7242 Email: dcp.drugcontrol@ct.gov Internet Web Site: http://www.ct.gov/dcp/dcd

Training	The Connecticut licensed pharmacist prescribing and dispensing intranasal and/or intramuscular Naloxone HCl shall provide appropriate training regarding the administration of Naloxone HCl to the person to whom the intranasal and/or intramuscular Naloxone HCl is dispensed.
Documentation	Each intranasal and intramuscular Naloxone HCl prescribed and dispensed, along with the required training, shall be documented in accordance with all applicable federal and state laws.
Recordkeeping	The record of each intranasal and intramuscular Naloxone HCl prescribed and dispensed, along with the required training, shall be maintained for a minimum of three years in accordance with all applicable federal and state laws.
Computer	The pharmacist prescribing and dispensing Naloxone HCl outside the
Access	licensed pharmacy premise may access the licensed pharmacy premise's
	computer system while <u>actively</u> prescribing and dispensing Naloxone HCl
	outside the licensed pharmacy premise. Computer access may be via
	telephone, remote access, or another form of communication accepted and approved by the Commission of Pharmacy.
HIPAA	The pharmacist prescribing and dispensing Naloxone HCl outside the
	licensed pharmacy premise shall comply with all HIPAA Rules.
	- HIPAA Privacy Rule (45 CFR Part 160 and Part 164, Subparts A and E)
	 HIPAA <u>Security</u> Rule (45 CFR Part 160 and Part 164, Subparts A and C) HIPAA <u>Breach Notification</u> Rule (45 CFR §164.408)
	- HIPAA <u>Breach Notification</u> Rule (45 CFR 9104.408) - HIPAA Enforcement Rule (45 CFR Part 160, Subparts C,D, and E)
Metrics	The pharmacist prescribing and dispensing Naloxone HCl outside the licensed
Wictifes	pharmacy premise shall report the total number of Naloxone HCl
	prescriptions dispensed to dcp.drugcontrol@ct.gov_within 72 hours of said
	prescribing and dispensing.